What is Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals is a clinical stage, Nasdaq listed (ticker ARWR) company developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, our therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Our RNAi-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. (source)

Arrowhead Pharmaceuticals Employee Count

Number of Arrowhead Pharmaceuticals employees:

134 employees

Last updated 10/1/19

---

Arrowhead Pharmaceuticals Revenue Totals

Arrowhead Pharmaceuticals annual revenue:

• FY 2021: $138 million
• FY 2020: $87.9 million
• FY 2019: $168 million
• FY 2018: $16 million
• FY 2017: $31 million
• FY 2016: $158,333
• FY 2015: $382,000

---

Arrowhead Pharmaceuticals annual net income:

• FY 2021: $140 million net loss
• FY 2020: $84 million net loss
• FY 2019: $67 million
• FY 2018: $54 million net loss
• FY 2017: $34 million net loss
• FY 2016: $81 million net loss
• FY 2015: $91 million net loss

---

Please note that some of these numbers are easier to find than others. A few of these Arrowhead Pharmaceuticals statistics come from their own reports, but some are based on news reports and not official company tallies. No information contained on DMR should be relied upon to make investment decisions. Basically, this is the best I can find and I don’t guarantee anything to be 100%.

Related Categories:

Related Tags: